Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Methods Patients with a UC diagnosis who initiated tofacitini...
Saved in:
| Published in | BMC gastroenterology Vol. 22; no. 1; pp. 177 - 11 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
09.04.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-230X 1471-230X |
| DOI | 10.1186/s12876-022-02215-y |
Cover
| Abstract | Background
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.
Methods
Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation).
Results
Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3–6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib.
Conclusions
Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. |
|---|---|
| AbstractList | Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], [greater than or equai to] 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with [greater than or equai to] 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with [greater than or equai to] 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and [greater than or equai to] 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3-6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and [greater than or equai to] 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.BACKGROUNDTofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation).METHODSPatients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation).Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3-6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib.RESULTSAmong patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3-6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib.Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required.CONCLUSIONSAmong patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Methods Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation). Results Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3–6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Conclusions Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Methods Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation). Results Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3–6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Conclusions Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Methods Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or [greater than or equai to] 2; minimum of 12 months prior to tofacitinib initiation). Results Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], [greater than or equai to] 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with [greater than or equai to] 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with [greater than or equai to] 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and [greater than or equai to] 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3-6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and [greater than or equai to] 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Conclusions Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Keywords: Tofacitinib, Small molecule Janus kinase inhibitor, Tumour necrosis factor inhibitor (TNFi), Vedolizumab, Ulcerative colitis, Adherence, Oral corticosteroid Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Methods Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation). Results Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3–6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Conclusions Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database. Patients with a UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor inhibitor (TNFi) treatment between May 2018 and July 2019 were identified from the Optum Research Database. Demographic and clinical characteristics of patients who initiated tofacitinib, vedolizumab or TNFi were described. Oral corticosteroid use prior to and following tofacitinib initiation was evaluated. Tofacitinib adherence (proportion of days covered) and continuation was assessed for 6 months following initiation. Analyses were descriptive and stratified by prior biologic use (naïve, 1 or ≥ 2; minimum of 12 months prior to tofacitinib initiation). Among patients initiating tofacitinib (N = 225), mean age was 45.6 (SD 16.5) years and 50.2% were female. Of these, 43 (19.1%) patients were biologic-naïve and 182 (80.9%) had prior biologic use (92 [40.9%], 1 prior biologic; 90 [40.0%], ≥ 2 prior biologics). Among patients with 1 prior biologic, 82.6% were previously treated with a TNFi. Among patients with ≥ 2 prior biologics, 54.4% were previously treated with vedolizumab and a TNFi, 16.7% with two TNFi and 28.9% with ≥ 3 prior biologics. In the 6 months prior to tofacitinib initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively). The proportion of patients with ongoing oral corticosteroid use 3-6 months after tofacitinib initiation decreased to 13.3% (9.3%, 18.5% and 10.0% for biologic-naïve, 1 and ≥ 2 prior biologics, respectively), and 19.6% of patients discontinued oral corticosteroid use during the 6 months after tofacitinib initiation. Overall, tofacitinib adherence, as determined by the mean proportion of days covered during the 6-month follow-up, was 0.7 (median 0.8). During the 6-month follow-up, 84.9% of patients continued tofacitinib. Among patients with UC initiating tofacitinib, the majority had prior biologic use. Tofacitinib adherence was high, discontinuation was low and oral corticosteroid utilisation decreased irrespective of prior biologic use. Further research with longer follow-up and a larger sample size is required. |
| ArticleNumber | 177 |
| Audience | Academic |
| Author | Khan, Nabeel Peterson-Brandt, Jesse Chiorean, Michael V. Allegretti, Jessica R. Cappelleri, Joseph C. Chastek, Benjamin Guo, Xiang Salese, Leonardo Sharma, Puza P. Bell, Elizabeth J. |
| Author_xml | – sequence: 1 givenname: Michael V. surname: Chiorean fullname: Chiorean, Michael V. organization: Swedish Medical Center – sequence: 2 givenname: Jessica R. surname: Allegretti fullname: Allegretti, Jessica R. organization: Brigham and Women’s Hospital – sequence: 3 givenname: Puza P. surname: Sharma fullname: Sharma, Puza P. organization: Pfizer Inc – sequence: 4 givenname: Benjamin surname: Chastek fullname: Chastek, Benjamin email: benjamin.chastek@optum.com organization: Optum Life Sciences, HEOR – sequence: 5 givenname: Leonardo surname: Salese fullname: Salese, Leonardo organization: Pfizer Inc – sequence: 6 givenname: Elizabeth J. surname: Bell fullname: Bell, Elizabeth J. organization: Optum Life Sciences, HEOR – sequence: 7 givenname: Jesse surname: Peterson-Brandt fullname: Peterson-Brandt, Jesse organization: Optum Life Sciences, HEOR – sequence: 8 givenname: Joseph C. surname: Cappelleri fullname: Cappelleri, Joseph C. organization: Pfizer Inc – sequence: 9 givenname: Xiang surname: Guo fullname: Guo, Xiang organization: Pfizer Inc – sequence: 10 givenname: Nabeel surname: Khan fullname: Khan, Nabeel organization: Perelman School of Medicine, University of Pennsylvania |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35397501$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kttq3DAQhk1JaQ7tC_SiCHqTizq1JEuybwoh9BAIFEoLvROyNNooeKWt5E2ap-mrdrybNAdKbIzE6Pt_MeN_v9qJKUJVvabNEaWdfF8o65SsG8bmj4r6-lm1R1tFa8abnzv39rvVfikXTUNVx_iLapcL3ivR0L3qzzcwY32V8uiIPTfZ2AlyKFOw5R2ZMphpCXEi8HuFZYgWCjER0ZQRSQXhFBxZT2EMxUwhRZI8WeEOVWVrAI5chemcTMkbG6YQw0B8ymSZHGQ8xgNS4BIykPVo51K4BLxhRLa8rJ57MxZ4dbMeVD8-ffx-8qU--_r59OT4rLayUVMN3g_Si65XXA0GWGsb1zlnByFs40VLh65xSgnOlJBtpwTjvTeCK-8540ryg-p06-uSudCrHJYmX-tkgt4UUl5oM7c8graUC7DgByZ92_Khp84xZhVtcabgOHp92Hqt1sMSnMVRZDM-MH14EsO5XqRL3fV92zOKBoc3Bjn9WkOZ9DIUC-NoIqR10UwiJmQvZ_TtI_QirXPEUSElWIMNU3lHLQw2EKJPeK-dTfWx7PGRXTd7Hf2HwtfBEn92BB-w_kDw5n6j_zq8jRcC3RawOZWSwWsMwCYm6BxGTRs9J1lvk6wxxXqTZH2NUvZIeuv-pIhvRQXhuIB8N40nVH8B1z0KTg |
| CitedBy_id | crossref_primary_10_1007_s10620_023_08063_4 crossref_primary_10_1093_ecco_jcc_jjad153 crossref_primary_10_1080_17474124_2022_2106216 crossref_primary_10_1186_s12876_022_02298_7 |
| Cites_doi | 10.1016/S0140-6736(16)32126-2 10.1111/apt.15689 10.1377/hlthaff.2014.0038 10.1053/j.gastro.2015.05.036 10.1093/ecco-jcc/jjz203.100 10.1053/j.gastro.2020.01.006 10.1016/j.dld.2019.10.003 10.1159/000496739 10.1016/j.cgh.2012.02.004 10.1016/j.cgh.2018.11.035 10.1093/ecco-jcc/jjaa145 10.3390/jcm9072177 10.1370/afm.1364 10.1002/0471602396 10.1056/NEJMoa1606910 10.1093/aje/kwq433 10.1093/ecco-jcc/jjx009 10.1093/ecco-jcc/jjaa075 10.1080/01621459.1958.10501452 10.1111/j.1524-4733.2007.00213.x 10.1016/j.cgh.2020.06.050 10.1007/s10620-019-05492-y 10.1056/NEJMoa1112168 |
| ContentType | Journal Article |
| Copyright | Pfizer Inc. and The Author(s) 2022 corrected publication 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
| Copyright_xml | – notice: Pfizer Inc. and The Author(s) 2022 corrected publication 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12876-022-02215-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-230X |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_c135ecefb26f443b91dd22c714975ed3 PMC8994921 A699996881 35397501 10_1186_s12876_022_02215_y |
| Genre | Journal Article |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QP 7QR 7T5 7XB 8FD 8FK AZQEC DWQXO FR3 H94 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-effb6f589737bae24c0d8ddcb55c0f541b80d775327564875239fa537ff323763 |
| IEDL.DBID | M48 |
| ISSN | 1471-230X |
| IngestDate | Wed Aug 27 01:20:58 EDT 2025 Thu Aug 21 18:20:58 EDT 2025 Thu Sep 04 15:10:20 EDT 2025 Fri Jul 25 19:52:12 EDT 2025 Tue Jun 17 21:01:50 EDT 2025 Tue Jun 10 20:48:59 EDT 2025 Thu Jan 02 22:54:23 EST 2025 Tue Jul 01 04:12:08 EDT 2025 Thu Apr 24 23:06:49 EDT 2025 Sat Sep 06 07:35:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Adherence Tofacitinib Small molecule Janus kinase inhibitor Tumour necrosis factor inhibitor (TNFi) Vedolizumab Oral corticosteroid Ulcerative colitis |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-effb6f589737bae24c0d8ddcb55c0f541b80d775327564875239fa537ff323763 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/c135ecefb26f443b91dd22c714975ed3 |
| PMID | 35397501 |
| PQID | 2652032716 |
| PQPubID | 44673 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c135ecefb26f443b91dd22c714975ed3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8994921 proquest_miscellaneous_2649256961 proquest_journals_2652032716 gale_infotracmisc_A699996881 gale_infotracacademiconefile_A699996881 pubmed_primary_35397501 crossref_citationtrail_10_1186_s12876_022_02215_y crossref_primary_10_1186_s12876_022_02215_y springer_journals_10_1186_s12876_022_02215_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-09 |
| PublicationDateYYYYMMDD | 2022-04-09 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC gastroenterology |
| PublicationTitleAbbrev | BMC Gastroenterol |
| PublicationTitleAlternate | BMC Gastroenterol |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | S Honap (2215_CR11) 2020; 14 JA Cramer (2215_CR19) 2008; 11 EA Bayliss (2215_CR17) 2012; 10 R Weisshof (2215_CR13) 2019; 64 M Harbord (2215_CR25) 2017; 11 EL Kaplan (2215_CR21) 1958; 53 WJ Sandborn (2215_CR3) 2012; 367 JD Feuerstein (2215_CR6) 2020; 158 P Hoffmann (2215_CR10) 2020; 9 GR Lichtenstein (2215_CR5) 2020; 14 C Ha (2215_CR7) 2012; 10 2215_CR27 2215_CR26 PJ Wallace (2215_CR14) 2014; 33 T Dassopoulos (2215_CR24) 2015; 149 M Chaparro (2215_CR9) 2021; 15 H Quan (2215_CR18) 2011; 173 VBC Biemans (2215_CR8) 2020; 51 L Lair-Mehiri (2215_CR12) 2020; 52 WJ Sandborn (2215_CR22) 2019; 17 G van Belle (2215_CR20) 2004 R Ungaro (2215_CR1) 2017; 389 P Deepak (2215_CR23) 2020; 19 2215_CR16 S Danese (2215_CR2) 2019; 37 2215_CR15 WJ Sandborn (2215_CR4) 2017; 376 |
| References_xml | – volume: 389 start-page: 1756 issue: 10080 year: 2017 ident: 2215_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(16)32126-2 – ident: 2215_CR15 – volume: 51 start-page: 880 issue: 9 year: 2020 ident: 2215_CR8 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.15689 – volume: 33 start-page: 1187 issue: 7 year: 2014 ident: 2215_CR14 publication-title: Health Aff (Millwood) doi: 10.1377/hlthaff.2014.0038 – volume: 149 start-page: 238 issue: 1 year: 2015 ident: 2215_CR24 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.05.036 – volume: 14 start-page: S100 year: 2020 ident: 2215_CR5 publication-title: J Crohns Colitis. doi: 10.1093/ecco-jcc/jjz203.100 – volume: 158 start-page: 1450 issue: 5 year: 2020 ident: 2215_CR6 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.006 – volume: 52 start-page: 268 issue: 3 year: 2020 ident: 2215_CR12 publication-title: Dig Liver Dis doi: 10.1016/j.dld.2019.10.003 – ident: 2215_CR27 – volume: 37 start-page: 266 issue: 4 year: 2019 ident: 2215_CR2 publication-title: Dig Dis doi: 10.1159/000496739 – volume: 10 start-page: 1002 issue: 9 year: 2012 ident: 2215_CR7 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.02.004 – ident: 2215_CR16 – volume: 17 start-page: 1541 issue: 8 year: 2019 ident: 2215_CR22 publication-title: Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2018.11.035 – volume: 15 start-page: 35 issue: 1 year: 2021 ident: 2215_CR9 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjaa145 – volume: 9 start-page: 2177 issue: 7 year: 2020 ident: 2215_CR10 publication-title: J Clin Med doi: 10.3390/jcm9072177 – volume: 10 start-page: 126 issue: 2 year: 2012 ident: 2215_CR17 publication-title: Ann Fam Med doi: 10.1370/afm.1364 – volume-title: Biostatistics: a methodology for the health sciences year: 2004 ident: 2215_CR20 doi: 10.1002/0471602396 – volume: 376 start-page: 1723 issue: 18 year: 2017 ident: 2215_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1606910 – volume: 173 start-page: 676 issue: 6 year: 2011 ident: 2215_CR18 publication-title: Am J Epidemiol doi: 10.1093/aje/kwq433 – volume: 11 start-page: 769 issue: 7 year: 2017 ident: 2215_CR25 publication-title: J Crohns Colitis. doi: 10.1093/ecco-jcc/jjx009 – volume: 14 start-page: 1385 issue: 10 year: 2020 ident: 2215_CR11 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjaa075 – volume: 53 start-page: 457 issue: 282 year: 1958 ident: 2215_CR21 publication-title: J Am Stat Assoc doi: 10.1080/01621459.1958.10501452 – ident: 2215_CR26 – volume: 11 start-page: 44 issue: 1 year: 2008 ident: 2215_CR19 publication-title: Value Health doi: 10.1111/j.1524-4733.2007.00213.x – volume: 19 start-page: 1592 issue: 8 year: 2020 ident: 2215_CR23 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.06.050 – volume: 64 start-page: 1945 issue: 7 year: 2019 ident: 2215_CR13 publication-title: Dig Dis Sci doi: 10.1007/s10620-019-05492-y – volume: 367 start-page: 616 issue: 7 year: 2012 ident: 2215_CR3 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1112168 |
| SSID | ssj0017823 |
| Score | 2.331115 |
| Snippet | Background
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and... Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid... Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and... Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 177 |
| SubjectTerms | Adherence Adrenal Cortex Hormones - therapeutic use Biological Products - therapeutic use Codes Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Comorbidity Corticosteroids Crohn's disease Drug therapy Female Gastroenterology Hepatology Human subjects Humans Inflammatory bowel disease Internal Medicine Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Patient outcomes Patients Piperidines - therapeutic use Pyrimidines Regulatory approval Small molecule Janus kinase inhibitor Software Steroids Tofacitinib Tumor necrosis factor Tumors Tumour necrosis factor inhibitor (TNFi) Ulcerative colitis Vedolizumab |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gICMhcaBREzu2k2NBVBVSOSAq9WbFLxFplVS72UN_DX-VGccJTRFw4bCXnbHX9ow9M-vxN4S85VLxSliRW4PXjFzIvPEeNh5rKlOX3MsC3zuff5FnF9XnS3F5o9QX5oRN8MDTwh3bkgtvfTBMhqripimdY8wq8OyV8C7ifIIZm4OpdH8Ado_PT2RqebyDU1hhsi3DTyny65UZimj9v5_JN4zS7YTJW7em0RidPiD3kxdJT6bRPyR3fP-I3D1P9-SPyY-v4P_lEQ2V2jUk8xFdcsupX3COd7TtgXXADvHZx3boHAWd3KRsHzoEmiBYd1MH3lH8D5eOQ2htN3Z9Zyg4wBRL6yD8BBAoWF2_9XS_sX4CGIdfwHS73RNycfrp28ezPJViyK0s1Jj7EIwMom4UV6b1rLKFq52zRghbBFGVpi6cgtAH0eQxBmK8Ca3gKgSOeTf8KTnoh94_J7Q13hmmAjO8AmPoDLg4vpKi4eBKMltkpJwlo23CKcdyGRsd45Va6kmaGiSpozT1dUbeL22uJpSOv3J_QIEvnIiwHb8AvdNJ7_S_9C4j71BdNJ4DMDzbpucMMElE1NInssFYsq7LjByuOGH_2jV5Vjidzo-dZlJgaXsIZjPyZiFjS8yJ6_2wRx4ElpSNhC6eTfq5TIkL8DNFARS10tzVnNeUvvse0cUhAId-oeXRrOO_hvXnNX3xP9b0JbnH4h6t8qI5JAfjdu9fgc83mtdxe_8E8qFVwQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4k1KQUZC4kCjJnFsJydUEFWFVA6ISnuz4hdEWiVlkz301_BXO-N4U1JED3tZP9beedvjbwh5x4RkJTc8NRqvGRkXae0cCF5Rl7rKmRMZvnc--yZOz8uvK76KB25DTKvc6cSgqG1v8Iz8qBAci32De__x4neKVaPwdjWW0LhL7uXgqiBXy9UccOVg_djuoUwljgbQxRJTbgv85Dy9XBijgNn_r2b-yzTdTJu8cXcaTNLJI_Iw-pL0eCL-Y3LHdU_I_bN4W_6U_PkOXmAaMFGpWQIzH9I5w5y6Ge14oE0HXXucEB9_bPrWUuDMdcz5ob2nEYh1mCZwluJJLh1735h2bLtWU3CDKRbYQRAKaKBge93G0e3auAlmHH4Bk-6GZ-T85MuPz6dpLMiQGpHJMXXea-F5VUsmdeOK0mS2stZozk3meZnrKrMSAiDElMdIqGC1bziT3jPMvmHPyV7Xd-4loY12VhfSF5qVYBKtBkfHlYLXDBzKwmQJyXeUUSailWPRjLUKUUsl1ERNBZRUgZrqMiEf5jEXE1bHrb0_IcHnnoizHb7oNz9VFFtlcsadcV4Xwpcl03VuLSxPQlwpubMsIe-RXRRqA1ieaeKjBtgk4mqpY1FjRFlVeUIOFj1Bis2yecdwKmqRQV3zfELezs04EjPjOtdvsQ_CS4pawBQvJv6ct8Q4eJs8gxa54NzFnpctXfsrYIxDGA7zwsjDHY9fL-v__-n-7bt4RR4UQfrKNKsPyN642brX4NON-k0Q3Ctdd0y6 priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgL4s1CQUZC4kAjEj-TY1lRVUjlgKjUmxW_RKRVUm2yh_4a_ioziTc05SFxyGU9duydGc9MZvyZkLdcaS6kk5mzmGbkUmVVCKB4rBK2LHhQOZ53PvuiTs_F5wt5kWBy8CzM9fx9UaoPPeyfGstkGT6FzK5ukzsSNl4s31ur9ZwxAEvH94di_thvYXhGfP7fd-FrZuhmieSNPOlofk4ekPvJb6THE6MfkluhfUTunqXM-GPy4yt4fNmIf0rdEoT5iM7V5DTMyMY9rVsg7XBAPOix7RpPQQo3qb6HdpEm0NV-GiB4il9t6dDF2jVD0zaWgstL8TIdBJyABgp2NmwD3W1cmCDF4Q1YYNc_Iecnn76tT7N0-ULmVK6HLMRoVZRlpbm2dWDC5b703lkpXR6lKGyZew3BDuLHY9TDeBVryXWMHCtt-FNy0HZteE5obYO3TEdmuQDz5y04NUEoWXFwHpnLV6TYc8a4hEyOF2RszBihlMpM3DTASTNy01ytyPu5z-WEy_FP6o_I8JkSMbXHH0DUTFJR4wougwvRMhWF4LYqvIfpaYghtQyer8g7FBeDmg_Tc3U6wACLRAwtc6wqjB7LsliRwwUlaKxbNu8FzqQdozdMSbzMHsLXFXkzN2NPrIJrQ7dDGoSSVJWCIZ5N8jkviUvwLGUOLXohuYs1L1va5vuIJw4hN4wLPY_2Mv5rWn__T1_8H_lLco-N2iiyvDokB8N2F16BPzfY16Mi_wRa7EYi priority: 102 providerName: Springer Nature |
| Title | Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis |
| URI | https://link.springer.com/article/10.1186/s12876-022-02215-y https://www.ncbi.nlm.nih.gov/pubmed/35397501 https://www.proquest.com/docview/2652032716 https://www.proquest.com/docview/2649256961 https://pubmed.ncbi.nlm.nih.gov/PMC8994921 https://doaj.org/article/c135ecefb26f443b91dd22c714975ed3 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central (PMC) customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1471-230X dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: M48 dateStart: 20011001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1471-230X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017823 issn: 1471-230X databaseCode: C6C dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dixMxEA_3AeKL-G31LBEEH7zV3WST7D6IXMsdh9BDigfFl9BkEy2UXe0H2L_Gf9WZ7Me553kPLbSZZJPMTGZmM_mFkNdcKp4KKyJrcJuRCxnlzoHisTw1WcKdjPG88-RCnl-mn2Zitkfa646aCVzfGNrhfVKXq-W7Xz93H0HhPwSFz-T7NayxClNpGX4SEe32ySFYJoZSPkmvdhXAGoaEe1iQI3C9Z-0hmhvb6BmqgOf_76r9l9m6nlJ5bV81mKuz--Re42fSk1owHpA9Vz4kdybNTvoj8nsKHmIU8FKp7YM2H9Mu-5y6Dgl5TeclkFbYIB4MWVWLgoLULpt8IFp52oC0rusGXEHxLS_dVH5uF5tFuTAUXGSKl-8gQAUUULDLbuXodmldDUEOT8CEvPVjcnl2-mV8HjWXNURWxmoTOe-N9CLLFVdm7lhq4yIrCmuEsLEXaWKyuFAQHCHePEZJjOd-LrjynmNmDn9CDsqqdM8InRtXGKY8MzwFc1kYcIJcKkXOwdlkNh6QpOWMtg2SOV6osdQhosmkrrmpgZM6cFPvBuRtV-dHjeNxK_UIGd5RIgZ3-KNafdONSmubcOGs84ZJn6bc5ElRQPcUxJxKuIIPyBsUF42yC92z8-bAAwwSMbf0icwx2syyZECOepSg4bZf3AqcbhVEMylYDJOZyAF51RVjTcyaK121RRqEnpS5hCae1vLZDYkL8ERFDCWqJ7m9MfdLysX3gD8OITq0CzWPWxm_6tb_5_T57YN8Qe6yoH1pFOdH5GCz2rqX4O9tzJDsq5kaksPR6cXnKfway_EwvDsZBvWG7-no6x_ZLldi |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4s1CASOBONCoSfxKDgiVR7Wl3R5QK-3NjR-BlVZJ2ewK7a_hH_AbmcmrpIjeeshlPXbsnfE84vE3hLxiUjEurAiswWNGJmSQeg8bL065SSLmZYj3nSdHcnzCv0zFdIP87u7CYFplpxNrRe1Ki9_Id2IpsNg3uPfvz34EWDUKT1e7EhqNWBz49U8I2ap3-5-Av6_jeO_z8cdx0FYVCKwM1TLweW5kLpJUMWUyH3MbusQ5a4SwYS54ZJLQKfDiERgd3fmYpXkmmMpzhikkDMa9Rq5zFnLE6lfTPsCLwNqy7mJOIncq0P0KU3xjfCIRrAfGr64R8K8l-MsUXkzTvHBWW5vAvTvkduu70t1G2O6SDV_cIzcm7en8ffLrK3idQY3BSu0QCHqb9hnt1PfoyhXNCiAtcUC8bLIoZ47CTpi3OUa0zGkL_Fo1A3hH8csxXZZ5ZmfLWTEzFNxuigV9EPQCGijYer_wdDW3voE1hzdgkl_1gJxcCaseks2iLPxjQjPjnYlVHhvGwQQ7A46V51KkDBzY2IYjEnWc0bZFR8ciHXNdR0mJ1A03NXBS19zU6xF52_c5a7BBLqX-gAzvKRHXu_6hXHzTrZrQNmLCW5-bWOacM5NGzsH0FMSxSnjHRuQNiotG7QPTs1l7iQIWiTheelemGMEmSTQiWwNK0Bp22NwJnG61VqXP99iIvOybsSdm4hW-XCENwlnKVMIQjxr57JfEBHi3IoQWNZDcwZqHLcXse41pDmE_jAs9tzsZP5_W___TJ5ev4gW5OT6eHOrD_aODp-RWXO9EHoTpFtlcLlb-GfiTS_O83sSUnF611vgD57qI2A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglSouiDeBAkZC4kCjJnFsJ8flsSoLrRBQqTcrfkGkVVJtsof-Gv4qM3nRlIfEIZf12LHXM56ZzMxnQl4wIVnKDQ-NxjAj4yLMnQPBS_JUZzFzIsJ65-MTcXSars742aUq_i7bfQxJ9jUNiNJUtYfn1vcinonDBk5VicmzCT4xDy-uk92M5wLcr93FYvVlNUUSQAOysVjmjz1nCqnD7f_9dL6knq6mTl6Jn3ZqaXmL3BzsSbroGeA2ueaqO2TveIiY3yU_PoMlGHa4qNTMwZkP6JRlTt2EeNzQogLSGgfEApBNXVoK3Lke8n5o7ekAxtr0AzhL8WsubWtfmLItq1JTMIUpXrKDQBTQQEH_uo2j27VxPdQ4vAET75p75HT57uubo3C4lCE0IpJt6LzXwvMsl0zqwiWpiWxmrdGcm8jzNNZZZCU4QYgrj95QwnJfcCa9Z5iBw-6Tnaqu3ENCC-2sTqRPNEtBLVoNxo5LBc8ZGJWJiQISjzujzIBYjhdnrFXnuWRC9bupYCdVt5vqIiCvpj7nPV7HP6lf44ZPlIi13f1Qb76pQXSViRl3xnmdCJ-mTOextTA9Cb6l5M6ygLxEdlF4IsD0TDEUNsAiEVtLLUSOXmWWxQHZn1GCJJt588hwajhJGpUIjpfcg1sbkOdTM_bE7LjK1VukQYhJkQsY4kHPn9OSGAeLk0fQImecO1vzvKUqv3c44-CKw7jQ82Dk8V_T-vt_-uj_yJ-RvU9vl-rj-5MPj8mNpBPMNIzyfbLTbrbuCZh8rX46SPVPyLNSzQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-world+characteristics%2C+treatment+experiences+and+corticosteroid+utilisation+of+patients+treated+with+tofacitinib+for+moderate+to+severe+ulcerative+colitis&rft.jtitle=BMC+gastroenterology&rft.au=Chiorean%2C+Michael+V&rft.au=Allegretti%2C+Jessica+R&rft.au=Sharma%2C+Puza+P&rft.au=Chastek%2C+Benjamin&rft.date=2022-04-09&rft.pub=BioMed+Central+Ltd&rft.issn=1471-230X&rft.eissn=1471-230X&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12876-022-02215-y&rft.externalDocID=A699996881 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon |